Evidence map›Paper›PMID 24302752›Full record

ArticleThe Journal of clinical endocrinology and metabolism2014

Detection of thyroid cancer stem cells in papillary thyroid carcinoma.

Soon-Hyun Ahn, Ying C Henderson, Michelle D Williams, Stephen Y Lai, Gary L Clayman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. The Changing Face ofFrontiers in surgery · 2020
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. p63 inhibits CD44Experimental and therapeutic medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Soon-Hyun AhnDepartment of Otolaryngology-Head and Neck Surgery (S-H.A.), College of Medicine, Seoul National University Bundang Hospital, Kyunggi-do 463-707, South Korea; and Departments of Head and Neck Surgery (Y.C.H., S.Y.L., G.L.C.), Pathology (M.D.W.), Molecular and Cellular Oncology (S.Y.L.), and Cancer Biology (G.L.C.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030.
Ying C Henderson
Michelle D Williams
Stephen Y Lai
Gary L Clayman
Seoul National University Bundang Hospital · KRThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Regulation of Invasion and Metastasis by HIF-1 Oral Squamous Cell CarcinomaK08DE018061 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2006 to 2010
$631k
NCI NIH HHS CA16672NCI NIH HHS P30 CA016672NIDCR NIH HHS K08 DE018061
6 · The paper itself

Abstract

contextSpecial populations of cells that can efficiently initiate tumor growth have been characterized, and this feature supports the cancer stem cell theory. These cancer stem cell populations have been identified with CD44 and POU5F1. Most cancer stem cells express high levels of CD44 and low levels of CD24. In thyroid lesions, cancer stem cells have been detected in anaplastic carcinoma. However, little is known about the presence of cancer stem cells in papillary thyroid carcinoma (PTC), especially in recurrent PTC. OBJECTIVE AND

designPTC cells were labeled and sorted by flow cytometry to obtain two populations. Total RNA was prepared from cells with high CD44 and CD24 expressions (CD44+CD24+) and from cells with high CD44 and low CD24 expressions (CD44+CD24-). The expressions of the stem cell marker POU5F1 and several differentiated thyroid markers were measured via real-time PCR.

resultsCD44+CD24- cells were present in all PTCs tested, and the percentage of these cells was higher in clinically aggressive recurrent PTC than in less aggressive primary PTCs. Higher expression of POU5F1 was found in CD44+CD24- cells compared with that of CD44+CD24+ cells. The expression of POU5F1 was higher in thyrospheroids grown in serum-free condition than in cells grown in the presence of serum from the same patient, and the tumor was initiated in mice using thyrospheroids.

conclusionsThe percentage of CD44+CD24- cells varied from tumor to tumor. Our findings suggest that cancer stem cells are present in PTC.

Indexed as

AnimalsCarcinogenesisCarcinoma, PapillaryCell Line, TumorFlow CytometryHumansMiceNeoplastic Stem CellsThyroid GlandThyroid Neoplasms

Identifiers

PMID24302752
PMCPMC3913805
OpenAlexW2023445598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.